Yousif Capital Management LLC Sells 425 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Yousif Capital Management LLC decreased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,231 shares of the specialty pharmaceutical company’s stock after selling 425 shares during the period. Yousif Capital Management LLC’s holdings in Supernus Pharmaceuticals were worth $768,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Barclays PLC increased its holdings in Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after purchasing an additional 51,005 shares in the last quarter. Segall Bryant & Hamill LLC bought a new position in shares of Supernus Pharmaceuticals during the third quarter worth about $791,000. Geode Capital Management LLC grew its holdings in shares of Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after buying an additional 74,438 shares in the last quarter. Franklin Resources Inc. raised its position in Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after buying an additional 2,121 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Supernus Pharmaceuticals by 40.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company’s stock valued at $7,901,000 after acquiring an additional 73,118 shares in the last quarter.

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 700 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 9.30% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald began coverage on shares of Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 price objective on the stock.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $39.11 on Friday. The business has a 50-day moving average of $37.54 and a 200-day moving average of $35.10. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of 36.55 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.